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Abstract
Multiple sclerosis (MS) is a debilitating immune-mediated neurological disorder affecting
young adults. MS is primarily relapsing-remitting, but neurodegeneration and disability
accumulate from disease onset. The most commonly used mouse MS models exhibit a
monophasic immune response with fast accumulation of neurological damage that does not
allow the study of progressive neurodegeneration. The chronic relapsing and secondary
progressive EAE (pEAE) Biozzi ABH mouse model of MS exhibits a reproducible relapsing-
remitting disease course that slowly accumulates permanent neurological deficit and devel-
ops a post-relapsing progressive disease that permits the study of demyelination and neu-
rodegeneration. RNA sequencing (RNAseq) was used to explore global gene expression in
the pEAE Biozzi ABH mouse. Spinal cord tissue RNA from pEAE Biozzi ABH mice and
healthy age-matched controls was sequenced. 2,072 genes were differentially expressed
(q<0.05) from which 1,397 were significantly upregulated and 675 were significantly down-
regulated. This hypothesis-free investigation characterised the genomic changes that
describe the pEAE mouse model. The differentially expressed genes revealed a persistent
immunoreactant phenotype, combined with downregulation of the cholesterol biosynthesis
superpathway and the LXR/RXR activation pathway. Genes differentially expressed include
the myelination genes Slc17a7, Ugt8A and Opalin, the neuroprotective genes Sprr1A, Osm
andWisp2, as well as genes identified as MS risk factors, including RGs14 and Scap2.
Novel genes with unestablished roles in EAE or MS were also identified. The identification
of differentially expressed novel genes and genes involved in MS pathology, opens the
door to their functional study in the pEAE mouse model which recapitulates some of the
important clinical features of progressive MS.
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Introduction
Multiple sclerosis (MS) is a central nervous system disease that primarily affects young
adults. MS has a median survival expectancy of 40 years after diagnosis [1], while patients
start accumulating significant levels of disability early in disease progression, which adds a
substantial burden to their everyday lives. MS is an immune-mediated disorder, characterised
by demyelination and neurodegeneration [2]. The clinical presentation of MS is most com-
monly relapsing-remitting, but can also be primary progressive, where neurodegeneration
and disability accumulate from disease onset. Over time relapsing remitting MS acquires a
secondary progressive phenotype, with pathology accumulating between relapses [3]. Neuro-
logical symptoms in MS reflect focal inflammatory demyelinating lesions in the central ner-
vous system that affect saltatory conduction in the affected sites [2]. Accumulating
neurological disability is accompanied by disabling symptoms such as spasticity, tremor and
muscle stiffness [4].
The most commonly used mouse model for the study of MS is the experimental autoim-
mune encephalomyelitis (EAE) model. This model has been extensively used in research, pri-
marily in C57BL/6 mice immunised with myelin oligodendrocyte glycoprotein (MOG) peptide
35–55. These mice exhibit a monophasic immune response with fast accumulation of neuro-
logical damage, rendering them as perhaps not the most suitable EAE model to study progres-
sive neurodegeneration [5]. The SJL mouse strain is a strain that develops relapsing-remitting
disease following active immunisation, and is thus useful for the study of immune responses
that more closely compare to the human disease [6]. However, the severe clinical disease and
the low incidence of relapse in these mice makes it hard to study accumulating neurological
disability. Thus existing mouse models do not always address the neurodegenerative processes
that underlie primary or secondary progressive MS. The neurodegenerative component of MS
remains a challenge and is currently untreated [7], in contrast to significant advances in con-
trolling relapsing-remitting MS, which responds to immunosuppressive treatments [8–10].
Although the adaptive immune response drives relapsing disease and is sensitive to immune
modifying drugs that act in the periphery to prevent new lesion formation and active attacks
[7, 9], progressive neurodegenerative disease is probably driven by innate inflammatory
responses within the CNS, which are insensitive to current peripheral immunomodulatory
drugs in both progressive EAE and MS [7, 9, 11]. Additionally, it has been demonstrated that
neurodegeneration can persist beyond the elimination of clinical relapses in EAE [12], as
occurs in relapsing MS also [8]. Therefore there is a need to develop novel neuroprotective
therapeutic approaches to complement current immunomodulatory approaches. To address
this challenge, the study of chronic progressive EAE models, where the underlying pathological
chronic neurodegenerative mechanisms are present, is expected to provide valuable insight in
disease pathophysiology and potential therapeutic targets.
The chronic relapsing and secondary progressive EAE Biozzi ABH mouse model of MS
exhibits a reproducible relapsing-remitting disease course that slowly accumulates permanent
neurological deficit, which is followed by progressive neurodegeneration and disability
(pEAE), with associated residual signs of disease such as spasticity and tremor [13–16]. Histo-
logical studies of Biozzi ABH mouse spinal cord tissue reveal immune-mediated relapsing dis-
ease episodes that prime the CNS-microenvironment for persistent demyelination, gliosis, glial
cell activation, axonal and neuronal loss [16, 17]. Thus, the pEAE mouse model permits the
study of mechanisms involved in the accumulation of neurological damage. Treatment of neu-
rodegeneration is likely to be critical in the treatment of progressive MS so this Biozzi ABH
mouse chronic model may provide a platform where strategies for neuroprotection and neu-
rorepair can be evaluated.
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In this study we used RNA sequencing (RNAseq) to explore gene expression in the spinal
cord of the post-relapsing secondary progressive pEAE Biozzi ABH mouse model. During the
post-relapsing pEAE disease stage the spinal cord is characterised by widespread demyelin-
ation, astrocytic gliosis, microglial activation and little to none immune infiltration [12, 17].
This hypothesis-free investigation of global gene expression aimed to characterise the genomic
changes that describe this pEAE mouse model and to generate the complete transcriptome of
the chronic, neurodegenerative EAE state. By studying the individual genes that were differen-
tially expressed, as well as the pathways that were differentially regulated, we were able to better
characterise the immunological, neurodegenerative and remyelinating components of the dis-
ease, as well as to propose genes and processes worth investigating further as potential thera-
peutic targets.
Materials and Methods
Animals
Adult (6–8 weeks), pathogen-free male Biozzi ABH mice were bred at Queen Mary University
of London. Methods of housing and other reporting elements relevant to the ARRIVE guide-
lines have been reported previously [18]. All procedures were approved by the Queen Mary
University of London Animal Welfare and Ethical Review Body and the United Kingdom Gov-
ernment Home Office Inspectorate. These studies where performed under Licence from the
UK Home Office and conformed to the United Kingdom Animals (Scientific Procedures) Act
1986 for the use of animals in research and Directive 2010/63/EU.
pEAE Induction
pEAE was induced in Biozzi ABH mice as described previously [18]. Briefly, young adult mice
were injected subcutaneously with 1 mg freeze-dried mouse spinal cord homogenate in
Freund’s adjuvant on days 0 and 7. Animals developed relapsing-remitting episodes of limb
paralysis with remission. Spasticity and slow deterioration of movement typically developed
after 2–3 relapses,*80–100 d post-induction [7, 9, 18]. Pathology in this model is largely
restricted to the spinal cord [13], so animal spinal cords were sampled during remission from
active paralytic episodes associated with hindlimb paralysis and weight loss [12, 17].
RNA Extraction and Sequencing
Three post-relapsing chronic pEAE animals were sacrificed following the development of spas-
ticity and tremor, at least 3 months after disease induction and after at least 3 clinical attacks as
indicated previously [19]. Three age-matched control mice that did not receive an injection
with spinal cord homogenate in Freunds adjuvant were also sacrificed. The spinal cord tissue
was removed, snap-frozen in liquid nitrogen and stored at -80°C. Frozen tissue was disrupted
in TRIzol1 Reagent on ice, using a rotor-stator homogeniser. Following 5 min incubation at
room temperature, chloroform was added to the samples, which were shaken, left to rest and
then centrifuged at 12000 g for 15 minutes. The resulting upper aqueous phase was washed
with 70% ethanol, mixed well and loaded on an RNeasy column. Thereafter the Qiagen
RNeasy1Mini Kit protocol was followed to extract and purify mRNA. mRNA integrity was
assessed by microfluidic capillary electrophoresis using the Agilent 2100 Bioanalyzer. All sam-
ples had a 260/280 ratio> 1.8 with RNA integrity number (RIN)> 9. RNA samples were pro-
cessed and sequenced at the UCL Genomics facility (UCL Institute of Child Health) using the
Illumina NextSeq 500 platform. Library preparation was performed using the TruSeq Stranded
Total RNA Library Prep Kit. 43 bp paired-end sequencing was performed and approximately
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18–25 million reads were obtained per sample. The dataset can be found in the Gene Expres-
sion Omnibus (GEO), accession number GSE78996.
Data Analysis
The FASTQ files generated for each sample were aligned to the UCSCMus musculusmm10
reference genome using the TopHat2 software (Illumina). Downstream analysis of these align-
ments was performed using Cufflinks software (Illumina). Cufflinks computes normalised
fragments per kilobase of exon per million fragments mapped (FPKM) which reflect the
expression levels of each mRNA molecule [20]. The reads were mapped to a total of 23,352
genes and 30,608 transcripts. To calculate p values, Cufflinks uses the Cuffdiff 2 algorithm that
estimates expression at transcript-level resolution and controls for variability across replicate
libraries. The Cuffdiff 2 statistical algorithm is described in depth in [21]. The Cuffdiff 2 algo-
rithm statistically analysed gene expression and produced a list of differentially expressed
genes in the pEAE tissue samples. The statistical analysis resulted in p values corrected for mul-
tiple testing with a default false discovery rate (FDR) of q<0.05.
To generate a heatmap for comparison of gene expression between all samples the UCL
Genomics facility (UCL Institute of Child Health) R-based pipeline was used. To compare the
lists of differentially expressed genes in pEAE with other published sets of genes, publically
available Venn analysis software was used (http://bioinfogp.cnb.csic.es/tools/venny/index.
html).
Ingenuity Pathway Analysis
Ingenuity pathway analysis (IPA, Ingenuity Systems1, www.ingenuity.com) was used to iden-
tify biological and molecular networks differentially regulated in the pEAE model. IPA is a
source of gene-interaction based pathway analysis including canonical pathways and a knowl-
edge database based on scientific findings. Statistically significant differentially expressed genes
at least 2-fold upregulated or downregulated were imported and analysed in the IPA database.
Based on the direct or indirect connectivity of genes as disclosed in the literature, genes were
mapped onto biological pathways and disease networks. Fisher’s exact test was performed to
validate assignation of a biological function or disease to a network. Canonical pathway analy-
sis was based on the identification of molecular pathways that are most significant for the
dataset.
Results
Differential Gene Expression Levels
The spinal cord tissue RNA sequencing resulted in approximately 18–25 million reads per
sample, which were aligned on theMus musculusmm10 reference genome. This resulted in the
identification of 23,352 annotated genes. Downstream statistical analysis of gene expression
between control and pEAE samples (Cuffdiff) resulted in 14,373 genes successfully tested for
differential expression (test status OK). Genes that were omitted from the analysis included
genes with insufficient alignments for testing (NOTEST), too shallowly sequenced genes
(LOWDATA), or genes with too many fragments aligned on the locus (HIDATA). It should be
noted here that two genes,Mbp and Plp1, were not successfully tested due to a HIDATA return.
These two genes are constituents of myelin, thus their involvement in this EAE model cannot
be overlooked. They both had O FPKM in the control mice, but very high average fragment
numbers (7939.56 and 2639.63 respectively) in the pEAE samples. Thus even though these
genes are not included in the statistical analysis and the Ingenuity pathway analysis, they are
Transcriptional Changes in the Progressive Experimental Encephalomyelitis Biozzi ABHMouse Model
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included in the lists of highly upregulated genes. From the mapped genes, 2,072 were differen-
tially expressed with a default false discovery rate (FDR) of q<0.05 (p<0.0072). More specifi-
cally 1,397 genes were significantly upregulated (q<0.05) and 675 genes were significantly
downregulated (q<0.05) (S1 and S2 Tables). The differential gene expression in the pEAE
samples compared with the control samples is visualised in Fig 1A. The MA plot presents the
ratio of FPKM expression values between the two conditions. All 14,373 genes are presented in
the plot with differentially regulated genes highlighted in colour. The volcano plot (Fig 1B)
presents the 14,373 genes, with genes with FDR<0.05 (p<0.0072, -log p<2.1426) visualised
in colour. In Fig 1B the statistically significant genes with a larger that 2-fold change in expres-
sion are presented in red and are the genes selected for further analysis. The heatmap in S1 Fig
demonstrates the hierarchical clustering within the three control and three pEAE spinal cord
samples which represents the differential expression of significantly regulated genes between
the control and pEAE groups.
Differential Gene Expression Analysis
The list of highly upregulated genes with a fold change of more than 16 (log2>4) reveals a
number of genes with established roles in inflammatory processes, such as antigen processing
and presentation, cell chemotaxis and cell adhesion (see S1 Table). This reveals a sustained
inflammatory response in the spinal cord of the post-relapsing pEAE model, consistent with
sustained microglial activity that remains following relapsing disease induced by the adaptive
immune response [9, 12]. These findings are in line with the histological spinal cord studies
during the progressive remitting stage of this EAE model, which have shown that the extensive
immunoglobulin deposition and infiltration of macrophages, CD4+ T lymphocytes, B lympho-
cytes and leucocytes described during relapses is greatly diminished [13, 16] and the remitting
spinal cord tissue is characterised by widespread demyelination, astrocytic gliosis and persis-
tent low grade microglial activation [9, 12, 13, 17].
Additionally, a number of highly upregulated genes are genes involved in non-inflammatory
biological functions, for example cell differentiation, proliferation, or ion transport. This list of
genes is presented in Table 1. The Gene Ontology biological processes that are implicated in
neurodegeneration, remyelination and related functions for each gene are also listed in Table 1.
Some genes with cell adhesion properties may also be implicated in regenerative, remyelinating
processes so they are included in the list. Associations with chronic EAE processes, differentia-
tion, de/remyelination, neurodegeneration and neuroprotection are also referenced in Table 1.
The list of most significantly downregulated genes with a fold change of more than 4
(log2>2), reveals that no genes are directly involved in inflammatory processes. Most of the
genes downregulated are involved in the cholesterol biosynthesis and metabolism superpath-
way. The list of the downregulated genes and their possible involvement in pEAE is presented
in Table 2. The Gene Ontology biological processes that are implicated in neurodegeneration,
remyelination and related functions for each gene are also listed, as well as associations with
chronic EAE processes, differentiation, de/remyelination, neurodegeneration and
neuroprotection.
Gene Network Construction
The gene network construction performed using the IPA platform aimed at creating a visual
tool to assess connections between differentially expressed genes. The direct or indirect con-
nectivity of genes as disclosed in the literature allows the assessment of connections between
any two given genes. A network was constructed for the upregulated genes with>3-fold
increase (Fig 2). A large number of functional direct and indirect connections can be seen
Transcriptional Changes in the Progressive Experimental Encephalomyelitis Biozzi ABHMouse Model
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Fig 1. Identification of differentially expressed genes. (A) MA plot representing the ratio of FPKM expression values
between chronic relapsing secondary progressive EAE samples and control samples plotted against their average. All
14,373 genes are plotted with significantly regulated genes (q<0.05) plotted in red. (B) Volcano plot presenting the 14,373
genes, with genes over the significance cut off at p <0.0072 (-log p <2.1426) plotted in grey. The statistically significant genes
with >2-fold change in expression are plotted in red.
doi:10.1371/journal.pone.0157754.g001
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Table 1. Most significantly upregulated genes (>16 fold change) with non-immunological functions.
Entrez Gene Entrez Name log2 fold
change
p value Gene ontology processes
associated with EAE
Association with chronic EAE processes,
differentiation, de/remyelination,
neurodegeneration, neuroprotection
Mbp myelin basic protein inf N/A Myelination Myelin constituent. Highly upregulated during
oligodendrocyte differentiation [22].
Plp1 proteolipid protein (myelin)
1
inf N/A Myelination Myelin constituent. Highly upregulated during
oligodendrocyte differentiation [22].
Mmp12 matrix metallopeptidase 12 inf 5.00E-
05
Positive regulation of
epithelial cell proliferation
involved in wound healing
Extracellular protease expressed in active
macrophages in MS lesions [23]. Involved in the
pathogenesis of Theiler’s murine encephalopathy,
induces demyelination and neurotoxicity [24].
Mcoln3 mucolipin 3 inf 5.00E-
05
Auditory receptor cell
differentiation, ion transport
Transient receptor potential channel (TRPML3)
involved in endocytosis [25], localized to lysosomes
and initiates neutralised lysosome exocytosis [26].
Atp6v0d2 ATPase, H+ transporting,
lysosomal V0 subunit D2
inf 5.00E-
05
ATP hydrolysis coupled
proton transport
Regulator of bone formation [27], no identiﬁed role.
Gpnmb glycoprotein
(transmembrane) nmb
7.09385 5.00E-
05
Cell adhesion Upregulated in Lewis rat EAE [28] and in an
amyotrophic lateral sclerosis mouse model, proposed
neuroprotective role [29].
Wisp2 WNT1 inducible signaling
pathway protein 2
6.21785 5.00E-
05
Cell adhesion, cell growth
regulation
Promotes neurite outgrowth in ganglioside deﬁcient
mice [30].
Plin4 perilipin 4 5.82633 5.00E-
05
Lipid storage regulation Protein present in spinal cord, involved in lipid droplet
storage [31]
Steap4 STEAP family member 4 5.37493 5.00E-
05
Ion transport Involved in osteoclast differentiation [32], no identiﬁed
role.
Ms4a7 membrane-spanning
4-domains, subfamily A,
member 7
5.34068 0.0001 Unknown No identiﬁed role. Associated with late-onset
Alzheimer’s disease [33]
Gm4841 predicted gene 4841 5.20993 0.0007 Unknown No identiﬁed role.
Cybb cytochrome b-245, beta
polypeptide
5.02298 5.00E-
05
Immune response, ion
transport
Superoxide generating enzyme Nox2, implicated in
microglial induced neurodegeneration [34]
Gpr65 G-protein coupled receptor
65
4.94688 0.0026 G-protein coupled receptor
signaling pathway
Proton sensing TDAG8 receptor, involved in
osteoclast regulation [35].
Ch25h cholesterol 25-hydroxylase 4.91766 5.00E-
05
Cholesterol metabolism Proposed susceptibility gene for Alzheimer’s disease
[36]. Proinﬂammatory enzyme, ch25h deletion
attenuates EAE [37].
Sprr1a small proline-rich protein 1A 4.60697 0.0026 Keratinocyte differentiation Protein expressed after neuronal injury, involved in
neuronal regeneration processes [38–40].
Ppl periplakin 4.55594 0.0026 Unknown Abundant in the brain, opioid receptor interacting
protein [41], no identiﬁed role.
Xdh xanthine dehydrogenase 4.4114 5.00E-
05
Cell differentiation/apoptosis Xanthine oxidase, the metabolic product of xanthine
dehydrogenase, is Implicated in EAE pathogenesis,
axonal and myelin loss [42].
Wfdc17 WAP four-disulﬁde core
domain 17
4.38813 5.00E-
05
Unknown Anti-neuroinﬂammatory microglial protein [43].
Osm oncostatin M 4.30594 0.0026 Immune response, peripheral
nervous system development
Upregulated in relapsing-remitting MS patients [44],
protective against demyelination in the Cuprizone-
induced demyelination model [45].
Ms4a6d membrane-spanning
4-domains, subfamily A,
member 6D
4.26213 5.00E-
05
Unknown No identiﬁed role.
Rnf186 ring ﬁnger protein 186 4.0977 0.0007 Unknown No identiﬁed role.
Gpr114 adhesion G protein-coupled
receptor G5
4.09084 0.00345 G-protein coupled receptor
signaling pathway
No identiﬁed role.
Tnfsf11 tumor necrosis factor
(ligand) superfamily,
member 11
4.07763 0.00275 Immune response, cell
differentiation
Osteoprotegerin ligand RANKL, important osteoclast
differentiation factor [46]. Upregulated in MS patients
[47, 48].
(Continued)
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between membrane receptors that take part in the response and maturation processes of the
immune system. Membrane receptors that belong to the major histocompatibility complex
(H2 gene family receptors) group together since they directly interact with each other to
orchestrate the autoimmune response. The constructed network illustrates the secreted chemo-
kines Ccl3l3, Ccl4 and Ccl5 as hubs for multiple signaling connections. The connections
between the upregulated members of the complement system, C2, C3, C4a/C4b, C1s, C1r, C1qa
and C1qb are also depicted. Secreted Tnfsf11 that encodes for the receptor activator of nuclear
factor kappa-B ligand (RANKL) also acts as a hub for multiple gene connections. RANKL,
encoded by Tnfsf11, and its receptor RANK are central in regulating the function of dendritic
cells and are critically involved in the maintenance of the number and function of CD4+CD25+
regulatory T cells [65, 66] (also see discussion). The multiple indirect connections of the puta-
tive neuroprotectant oncostatin M (Osm; see discussion) are also presented. Ptpn6, a tyrosine
phosphatase with a role in inflammatory disease also forms many direct and indirect connec-
tions with the upregulated gene population.
The number of significantly downregulated genes that were involved in direct or indirect
connections was small, so this allowed for the construction of a network using all the signifi-
cantly downregulated genes with>2-fold increase (Fig 3). Interestingly but not surprisingly, the
gene that formed the most connections in the network was Insig1, an endoplasmic reticulum
receptor that plays an important role in the downregulation of cholesterol biosynthesis. The
connections betweenHmgcr and Cyp51a1, both enzymes involved in cholesterol metabolism
(see discussion), and other downregulated genes are also depicted in the constructed network.
Canonical Pathway Analysis
For the canonical pathway analysis, differentially expressed genes with a FDR of q<0.05 and a
fold change of at least 2 were selected (visualised in red in Fig 1B). This set of genes, comprising
of 851 upregulated and 150 downregulated genes was imported into the Ingenuity pathway
analysis platform (IPA, Ingenuity Systems1, www.ingenuity.com). The list of the 10 most sig-
nificantly regulated canonical pathways is presented in Table 3. As expected from the gene
analysis, the cholesterol biosynthesis superpathway was the most significantly downregulated
pathway, with 17/27 genes downregulated. The LXR/RXR regulation pathway, a pathway
emerging as a critical pathway in oligodendrocyte precursor cell (OPC) differentiation [67] was
significantly regulated, with 23/121 genes upregulated and 4/121 genes downregulated. The
rest of the significantly regulated canonical pathways were all upregulated pathways involved
in immune processes, namely the dendritic cell maturation pathway, the T helper cell differen-
tiation pathway, the pathway of hepatic fibrosis and hepatic stellate cell activation, the pathway
of altered T and B cell signaling in rheumatoid arthritis, the acute phase response signaling
pathway, the antigen presentation pathway, the complement system pathway and the pattern
Table 1. (Continued)
Entrez Gene Entrez Name log2 fold
change
p value Gene ontology processes
associated with EAE
Association with chronic EAE processes,
differentiation, de/remyelination,
neurodegeneration, neuroprotection
Serpina3i serine (or cysteine)
peptidase inhibitor, clade A,
member 3I
4.05241 5.00E-
05
Unknown No identiﬁed role.
B430306N03Rik RIKEN cDNA B430306N03
gene
4.04922 5.00E-
05
Unknown Unknown protein.
doi:10.1371/journal.pone.0157754.t001
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recognition receptors in recognition of bacteria and viruses. All the above pathways in many
instances overlap, with upregulated genes involved in tumour necrosis factor signaling, toll
receptor signaling or antigen presentation processes involved in more than one upregulated
pathway. The upregulation of pathways involved in immune processes further supports the
presence of persistently activated microglia in pEAE mice.
Table 2. Most significantly downregulated genes (>4 fold change).
Entrez Gene Entrez Name log2 fold
change
p value Gene ontology
processes
associated with
EAE
Association with chronic EAE processes,
differentiation, de/remyelination,
neurodegeneration, neuroprotection
Ttr transthyretin -4.43828 0.00265 Retinol metabolic
process, thyroid
hormone transport
Involvement in thyroxin transport, thyroxin promotes
OPC differentiation [49], is protective in
experimental autoimmune encephalomyelitis [50].
Slc17a7 solute carrier family 17 (sodium-
dependent inorganic phosphate
cotransporter), member 7
-4.25294 5.00E-
05
Transport, synaptic
transmission
Vesicle bound glutamate transporter (VGLUT1)
localised in glutamatergic axon-OPC synapses and
involved in myelination processes [51, 52].
A930006I01Rik RIKEN cDNA A930006I01 gene -3.47535 5.00E-
05
Unknown Unknown protein.
Idi1 isopentenyl-diphosphate delta
isomerase
-2.70827 5.00E-
05
Isoprenoid
biosynthetic process
Cholesterol synthesizing enzyme, downregulated in
Aβ treated neurons [53] and rat spinal cord injury
[54].
Hmgcs1 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1
-2.61103 5.00E-
05
Cholesterol
metabolism
Cholesterol rate limiting enzyme, negatively
regulated in rat spinal cord injury [54] and in a
dysmyelinating mouse model [55]. Induces OPC
migration and myelination failure [56].
Fam216b family with sequence similarity 216,
member B
-2.45922 5.00E-
05
Unknown No identiﬁed role.
Ugt8a UDP galactosyltransferase 8A -2.40356 5.00E-
05
Myelination, lipid
metabolism
Enzyme essential for myelination [57].
Depdc1b DEP domain containing 1B -2.403 5.00E-
05
Cell migration Promotes cellular de-adhesion and mitosis [58].
9630013A20Rik RIKEN cDNA 9630013A20 gene -2.34667 0.0025 Non-coding RNA Unknown role.
Mvd mevalonate (diphospho)
decarboxylase
-2.30806 5.00E-
05
Cholesterol
metabolism
Enzyme involved in cholesterol metabolism.
Sc4mol methylsterol monoxygenase 1 -2.25635 5.00E-
05
Lipid metabolism Enzyme involved in cholesterol metabolism and
LXR signaling [59].
Opalin oligodendrocytic myelin paranodal
and inner loop protein
-2.23362 5.00E-
05
Myelination Myelin protein, located in paranodal loop
membrane [60].
Cyp51 cytochrome P450, family 51 -2.17764 5.00E-
05
Cholesterol
metabolism
Enzyme involved in cholesterol metabolism.
Slc5a11 solute carrier family 5 (sodium/
glucose cotransporter), member 11
-2.13978 5.00E-
05
Ion transport Glucose transporter implicated in immune
modulation and apoptosis [61].
Ldlr low density lipoprotein receptor -2.13576 5.00E-
05
Cholesterol
metabolism
Involvement in LXR-induced myelination in
oligodendrocytes [62].
Aqp6 aquaporin 6 -2.13396 5.00E-
05
Transport No identiﬁed role.
Hmgcr 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase
-2.12073 5.00E-
05
Cholesterol
metabolism
Rate controlling enzyme in cholesterol metabolism,
upregulated in myelination [63], negatively
regulated in a dysmyelinating mouse model [55].
Sqle squalene epoxidase -2.11207 5.00E-
05
Cholesterol
metabolism
Rate limiting enzyme in sterol biosynthesis.
Smyd1 SET and MYND domain containing 1 -2.10952 5.00E-
05
Negative regulation
of transcription
Key factor in myogenic differentiation [64], no
identiﬁed role.
4930452G13Rik RIKEN cDNA 4930452G13 gene -2.03768 0.00025 Non-coding RNA Unknown role.
doi:10.1371/journal.pone.0157754.t002
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Comparison between pEAE and Microarray EAE Studies
To dissect the unique molecular characteristics of the pEAE mouse model, its comparison with
transcriptional studies of other EAE rodent models can provide valuable information about
genes and pathways that may be similarly or differently regulated between different models.
The comparison of the present pEAE study with other transcriptomic studies of EAE models
proved difficult, since lack of publicly available data, especially from older studies, as well as
differences in the methodology used, in animal species, strain and immunisation antigens
selected, in most cases did not allow direct comparison of the studies. In absence of MOG-
induced mouse EAE transcriptional data, the lists of differentially expressed genes from two
EAE microarray studies re-analysed in a meta-analysis performed by Raddatz et al. [68] were
selected to compare with the pEAE mouse data.
The first study was a MOG-induced relapsing EAE study performed on Dark Agouti rat spi-
nal cord tissue, where healthy rats were compared to the acute, remitting and relapsing states
of the disease [69]. The comparison of the differentially expressed pEAE genes with the differ-
entially upregulated or downregulated genes in the different disease states revealed some over-
lap between the two models (Fig 4). In the relapsing disease stage a large percentage of genes
overlapped with the pEAE gene dataset. This supports higher similarities between the relapsing
Fig 2. Network of direct and indirect gene connections between >3-fold upregulated genes.Network of direct and indirect gene connections as
predicted by Ingenuity Pathway Analysis software. >3-fold upregulated mouse genes were uploaded on the IPA platform to establish a network of their
published connections.
doi:10.1371/journal.pone.0157754.g002
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EAE phenotype and the progressive phenotype. All the lists of different or common genes at all
disease stages can be found in S3 Table.
The second study was a PLP-induced acute EAE study of spinal cord tissue performed in
SJL/J mice [70]. The comparison of the two different mouse EAE models revealed some simi-
larities in gene expression (Fig 5). Since this comparison was performed between the acute dis-
ease stage of a monophasic EAE mouse model and the progressive EAE model, the lists of
unique pEAE genes are informative in regards to the nature of genes differentially regulated in
the chronic disease phase. The lists of different or common genes upregulated and downregu-
lated in the two mouse EAE models can be found in S4 Table.
Comparison between pEAE and Other RNAseq EAE Studies
RNAseq is a relatively new transcriptomic analysis technology and so far only very few RNAseq
studies have addressed MS and EAE models. An advantage of RNAseq is that the very small
amounts of RNA required allow the identification of the transcriptome of cellular populations
rather than whole tissue. The single RNAseq study that investigated the whole transcriptome
in an EAE mouse model was performed on spinal cord microglia and monocyte-derived mac-
rophages isolated from different stages of MOG-induced EAE in C57BL/6 mice [71]. The dif-
ferentially regulated canonical pathways identified in microglia and monocyte derived
microglia during different disease stages were compared with our pEAE study. This
Fig 3. Network of direct and indirect gene connections between >2-fold downregulated genes.
Network of direct and indirect gene connections as predicted by Ingenuity Pathway Analysis software. >2-fold
downregulated mouse genes were uploaded on the IPA platform to establish a network of their published
connections.
doi:10.1371/journal.pone.0157754.g003
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Table 3. Tenmost significantly altered canonical pathways.
Ingenuity Canonical Pathways -log(p
value)
Ratio Down-
regulated
No
change
Up-
regulated
No overlap
with
dataset
Molecules
Superpathway of Cholesterol
Biosynthesis
1.59E01 6.3E-
01
17/27
(63%)
0/27
(0%)
0/27 (0%) 10/27 (37%) HMGCS1, NSDHL, ACAT2, FDPS, HMGCR,
SC5D, MSMO1, LSS, SQLE, IDI1, DHCR24,
MVK, TM7SF2, HSD17B7, CYP51A1, MVD,
DHCR7
Dendritic Cell Maturation 1.53E01 2.25E-
01
2/169 (1%) 0/169
(0%)
36/169
(21%)
131/169
(78%)
PLCB2, H-2-AHLA-DQA1, FCGR1A, TNFRSF1A,
PIK3R5, PLCE1, TLR9, FCER1G, NFKBIA,
TREM2, TLR4, IL23A, IRF8, HLA-DMA, STAT1,
TYROBP, HLA-DRB5, HLA-DMB, IL1RL2, CD80,
TLR2, CD86, IL33, LTB, HLA-DQB1, TNFRSF1B,
MAP3K14, HLA-DOB, B2M, FCGR2A, PIK3CG,
PLCG2, HLA-A, FCGR2B, IL1A, COL2A1, ICAM1,
IKBKE
T Helper Cell Differentiation 1.48E01 3.58E-
01
0/67 (0%) 0/67
(0%)
24/67
(36%)
43/67 (64%) IL21R, TGFB1, TNFRSF1A, HLA-DQA1,
HLA-DQB1, TNFRSF1B, IL6R, ICOSLG/
LOC102723996, HLA-DOB, FCER1G, IL2RG,
IL10RA, TGFBR2, IL10RB, HLA-DMA, STAT1,
HLA-DRB5, STAT6, HLA-DMB, CD80, IL4R,
RORC, CD86, IL12RB1
Hepatic Fibrosis / Hepatic
Stellate Cell Activation
1.31E01 1.94E-
01
2/196 (1%) 0/196
(0%)
36/196
(18%)
158/196
(81%)
TGFB1, TNFRSF1A, IL6R, TNFSF8, LBP,
TNFSF13, IL10RA, TLR4, A2M, CCR5, IL1R1,
STAT1, EDN1, IL1RL2, LTB, CCL5, TNFSF11,
COL6A3, KDR, TNFRSF1B, CD14, IGFBP5,
FGF2, COL5A1, IGF1, IGF2, AGT, TGFBR2,
COL23A1, CCL2, IL1A, IL4R, COL2A1,
SERPINE1, FAS, COL13A1, ICAM1, HGF
Altered T Cell and B Cell
Signaling in Rheumatoid
Arthritis
1.27E01 2.96E-
01
1/81 (1%) 0/81
(0%)
23/81
(28%)
57/81 (70%) TLR7, TNFSF11, TGFB1, HLA-DQA1,
HLA-DQB1, TLR1, MAP3K14, TLR9, FCER1G,
TNFSF13, TLR4, IL23A, HLA-DMA, HLA-DRB5,
IL1A, HLA-DMB, CD80, TLR6, FAS, TLR2, CD86,
IL33, LTB
Acute Phase Response
Signaling
1.16E01 1.96E-
01
1/168 (1%) 0/168
(0%)
32/168
(19%)
135/168
(80%)
CFB, OSM, C3, SOCS3, TNFRSF1A, IL6R, LBP,
C1R, NFKBIA, A2M, C4A/C4B, C2, IL1R1, VWF,
ITIH2, IL33, CP, TNFRSF1B, RBP1, MAP3K14,
SERPINA3, HMOX1, PIK3CG, OSMR, AGT,
CEBPB, IL1A, FTL, SERPINE1, C1S, SERPING1,
TTR, IKBKE
Antigen Presentation Pathway 1.16E01 4.32E-
01
0/37 (0%) 0/37
(0%)
16/37
(43%)
21/37 (57%) HLA-E, CD74, HLA-DQA1, NLRC5, HLA-G,
HLA-DOB, B2M, TAP1, HLA-A, TAP2, HLA-DMA,
HLA-DRB5, HLA-DMB, MR1, PSMB9, PSMB8
LXR/RXR Activation 1.1E01 2.23E-
01
4/121 (3%) 0/121
(0%)
23/121
(19%)
94/121
(78%)
C3, TNFRSF1A, HMGCR, LBP, PON3, TLR4,
C4A/C4B, LDLR, IL1R1, IL1RL2, IL33, MYLIP,
S100A8, SREBF1, TNFRSF1B, CD14, APOD,
ABCA1, MSR1, AGT, LYZ, CCL2, IL1A, LPL,
CYP51A1, APOE, TTR
Complement System 1.06E01 4.17E-
01
0/36 (0%) 0/36
(0%)
15/36
(42%)
21/36 (58%) ITGAM, CFB, C3, C1QB, ITGAX, ITGB2, C1R,
CFH, C3AR1, C1QA, C1QC, C4A/C4B, C2, C1S,
SERPING1
Role of Pattern Recognition
Receptors in Recognition of
Bacteria and Viruses
1.04E01 2.18E-
01
0/119 (0%) 0/119
(0%)
26/119
(22%)
93/119
(78%)
OSM, TGFB1, C3, TLR1, PIK3R5, TLR9, C3AR1,
C1QA, TLR4, SYK, IRF7, TLR6, TLR2, PTX3,
TLR7, CCL5, C1QB, CASP1, PIK3CG, PLCG2,
C1QC, PRKCD, NLRP3, IFIH1, IL1A, CLEC7A
doi:10.1371/journal.pone.0157754.t003
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Fig 4. Comparison of the differentially expressed pEAE genes with differentially expressed genes in MOG-induced EAE
in Dark Agouti rats at different disease stages. (A) Venn diagrams of upregulated and downregulated pEAE genes compared
with acute MOG-induced EAE. (B) Venn diagrams of upregulated and downregulated pEAE genes compared with remitting
MOG-induced EAE. (C) Venn diagrams of upregulated and downregulated pEAE genes compared with relapsing MOG-induced
EAE.
doi:10.1371/journal.pone.0157754.g004
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comparison allowed us to identify the microglial and macrophage pathways that overlap with
our dataset. It also allowed us to isolate pathways that are not enriched in microglial lineage
cells and that can be related to monocyte/microglial independent disease mechanisms such as
T-cell mediated immune processes, neurodegeneration, demyelination and remyelination. All
canonical pathways in our dataset with 3 or more genes identified within the pathway were
compared with the canonical pathways regulated in pre-symptomatic and active EAE (clinical
score 3) monocyte derived macrophages, as well as with pre-symptomatic and active EAE
microglial derived macrophages. As seen in the Venn diagrams in Fig 6A the majority of the
canonical pathways enriched in each macrophage population were common with the pEAE
dataset while some pathways were unique for the macrophage populations (all data in S5
Table). The unique canonical pathways in the pEAE dataset were plotted on a Venn diagram
(Fig 6B) to isolate the 71 canonical pathways consistently unique to our dataset between all
comparisons (S6 Table).
Comparison between Differentially Regulated Genes and MS
Susceptibility Genes
During the last years, genome-wide association studies (GWAS) and other large-scale genotyp-
ing projects have revealed that only a few common genetic variants exist that exert relatively
large MS risk, all of which are located in theHLA (human leucocyte antigen) locus. The
remainder of the genetic risk spectrum comprises of a number of susceptibility variants exert-
ing much smaller effects. So far, 110 independent SNPs outside the HLA locus have been iden-
tified to contribute to MS risk [72, 73]. A comparison between the published MS susceptibility
genes and the differentially regulated genes in the pEAE mouse spinal cord tissue could reveal
genes of specific interest to MS that also contribute to EAE pathology. Hoppmann et al. [74]
recently produced a list of 209 human genes mapped in proximity to the 110 MS susceptibility
loci. This list of mapped genes was compared with our set of upregulated and downregulated
genes to identify MS susceptibility genes that overlap with our dataset. 34/209 MS susceptibility
genes were significantly upregulated in the pEAE gene dataset, and 4/209 MS susceptibility
genes were downregulated (Fig 7). These 38 MS susceptibility genes are of particular interest
since their involvement in pEAE can highlight common disease processes.
Fig 5. Comparison of the differentially expressed pEAE genes with differentially expressed genes in PLP-induced EAE
in SJL/J mice during the acute disease phase. Venn diagrams of the comparisons between the upregulated and the
downregulated gene datasets.
doi:10.1371/journal.pone.0157754.g005
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Fig 6. Comparison between the regulated pathways of the pEAE dataset with presymptomatic and active EAE (clinical
score 3) monocyte derivedmacrophages, as well as with presymptomatic and active EAEmicroglial derivedmacrophages.
(A) Venn diagrams of each comparison set. (B) Venn diagram of the unique canonical pathways regulated only in pEAEmice
identified from the comparison of the chronic relapsing and secondary progressive EAE dataset with the macrophage populations.
doi:10.1371/journal.pone.0157754.g006
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Discussion
The aim of this RNAseq study was to transcriptionally characterise the pEAE Biozzi ABH
mouse model, to identify genes and molecular processes that may be specifically regulated in
the chronic progressive phase of this disease model and to identify novel MS targets. The spinal
cord transcriptional analysis revealed that a persistent immune response underlies the disease
with immune pathways and genes highly upregulated (S1 and S2 Tables, Table 3). Immune
Fig 7. Comparison between the differentially upregulated and downregulated genes in the pEAEmice and MS
susceptibility genes. (A) Venn diagram depicting the common genes between MS susceptibility genes (Hoppmann
et al., [74]) and upregulated EAE genes (34) and the common genes between the MS susceptibility genes and
downregulated EAE genes (4). (B) List of the common genes as identified in the Venn diagram.
doi:10.1371/journal.pone.0157754.g007
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pathways and responses established in EAE pathology are involved in the pEAE model, such as
the dendritic cell maturation pathway, the T helper cell differentiation pathway, the antigen
presentation pathway and the complement system. However, it is clear that the adaptive
immune response driven by T cells that induces relapsing disease is reduced during progressive
EAE, which is more associated with chronic microglial activation [9, 12, 17] as also appears to
be the case in neurodegeneration in MS that is associated with chronic microglial activation
[75]. Additionally, pathways and genes that seem to play an important role in the chronic dis-
ease progression were also revealed, such as the highly downregulated cholesterol biosynthesis
and the RXR/LXR activation pathways. Genes that increase susceptibility to MS were found
up- or downregulated in this model, providing insights into the relevance of this model for the
study of MS processes.
Genes Involved in Cellular Differentiation
Remyelination is a frequent event in MS lesions [76]. Shadow plaques, which are completely
remyelinated lesions, account for 10–20% of all lesions [77]. Remyelination was histopathologi-
cally described in pEAE mice [17] and characterises the secondary progressive phenotype of
this disease model. Here, the remarkable upregulation ofMbp and Plp1 expression in the pEAE
model confirms that active remyelination takes place during the progressive phase of the dis-
ease model.Mbp and Plp1 encode for myelin basic protein and proteolipid protein 1, both con-
stituent proteins of the myelin membrane, with a documented upregulation during
oligodendrocyte differentiation [22]. Remyelination in progressive EAE as well as MS is lim-
ited. The reduced ability for lesion remyelination has been attributed to neuronal loss, but also
the inability of OPCs to switch from a proliferating and migrating phenotype to a differentiat-
ing one. Genes involved in myelination significantly downregulated in the pEAE transcriptome
reveal significant clues to remyelination failure processes. Vesicle bound glutamate transporter
(VGLUT1), encoded by Slc17a7 is an axon terminal glutamate transporter required in neuro-
nal–OPC synapses to promote myelination processes [51, 52]. Slc17a7 downregulation in
pEAE reflects how neurodegeneration may inhibit myelination processes. Ugt8a was signifi-
cantly downregulated in the pEAE mouse. Ugt8a encodes for the enzyme ceramide glucosyl-
transferase, which is essential for galactosylceramide production and myelin integrity [57].
Opalin is a myelin membrane protein present in paranodal loops [60] which was also signifi-
cantly downregulated in the pEAE mouse. These dowregulated genes involved in myelination
present as promising targets for new remyelination strategies.
Attention should also be drawn to some regulated genes involved in cellular differentiation
processes with no identified role in EAE or MS. Smyd1 for example is a downregulated tran-
scriptional regulator identified as a key factor in myogenic differentiation [64] but with no
known role in EAE or MS. Another example of a highly upregulated gene isMcoln3, that
encodes a transient Ca2+ channel, (TRPML3), which is involved in auditory receptor cell differ-
entiation in mice [78]. Recently TRPML3 emerged as a transient receptor potential channel
(TRP) located in lysosomes responsible for lysosomal extrusion following their neutralisation
by bacterial infection [59]. The involvement ofMcoln3 in lysosomal homeostasis could impli-
cate it in autophagosomal processes that may be related to neurodegeneration. Another group
of upregulated genes involved in cellular differentiation include the H+ transporting ATPase
Atp6v0d2, the ion transporter Steap4, the proton sensing receptor Gpr65 (TDAG8) and the Nf-
κB ligand RANKL, encoded by Tnfsf11 (tumour necrosis factor superfamily member 11), all
involved in the regulation of osteoclast differentiation [27, 32, 35, 46]. The upregulation of
osteoclast differentiation molecules may reflect defects in bone remodelling in pEAE and MS,
or may reflect a yet unidentified involvement of this differentiation pathway in disease
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progression. It is interesting to note that RANKL is significantly upregulated in MS patient
serum [47, 48]. RANKL and its receptor RANK have a critical role in regulating the function of
dendritic cells and in maintaining the number and function of CD4+CD25+ regulatory T cells
[65, 66]. The involvement of RANKL in T cell regulation in active EAE was demonstrated in a
recent study where RANKL depletion prevented EAE development due to impaired T cell infil-
tration into the CNS [79]. Thus the upregulation of RANKL in our dataset and the upregulated
protein levels in MS patient serum may reflect the involvement of RANKL in T cell regulation
in EAE and MS.
Genes Involved in Neurodegeneration and Neuroprotection
Some genes upregulated in the pEAE model that are involved in immune processes have been
reported to also be involved in neurodegenerative processes. Matrix metallopeptidase 12
(Mmp12) is expressed in macrophages but has also been involved in inducing demyelination
and neurodegeneration before macrophage infiltration in Theiler’s murine encephalopathy
[24].Mmp12 was highly upregulated in pEAE highlighting the possibility that regulation of
Mmp12 levels could have a neuroprotective effect. Reactive oxygen species generating enzymes
such as Cybb, encoding for the superoxide-generating microglial enzyme Nox2 and xanthine
dehydrogenase (Xdh) were also upregulated in pEAE. Both enzymes have been implicated in
neurodegenerative processes [34, 42].
A gene with a well-documented role in neuroprotection was upregulated in the pEAE data-
set. Sprr1a, the small proline-rich protein A1, is a protein involved in keratinocyte differentia-
tion which is upregulated in neurons following experimental brain injury [38], and in sciatic
nerve and spinal cord sensory neurons following axotomy [39]. Sprr1a promotes neuronal out-
growth and is expressed soon after neuronal injury. Thus the upregulation of this gene indi-
cates the activation of a neuroprotective mechanism in the pEAE spinal cord and highlights a
potential therapeutic avenue that deserves further investigation. The transient channel
TRPML3, encoded by theMcoln3 gene and also known as cornifin-A, is a channel involved in
keratinocyte differentiation. An additional gene involved in keratinocyte complex formation,
Ppl which encodes periplakin was also upregulated in the pEAE mouse. It is possible that Ppl
may be part of the pathway that promotes axonal regeneration together with Sprr1A, so further
investigation of the involvement of Plp in neuroprotection would be of interest. Additional
genes with neuroprotective roles were also upregulated in the pEAE mouse model. Oncostatin
M, encoded by the Osm gene was found upregulated in the serum of a cohort of people with
relapsing-remitting MS [44], while oncostatin treatment protected against demyelination in
the Cuprizone-induced demyelination model [45]. Gpnmb is a transmembrane glycoprotein
also found upregulated in Lewis rat EAE [28] and in a mouse model of amyotrophic lateral
sclerosis [29]. A neuroprotective in vitro role has been proposed [29]. In a ganglioside deficient
mouse modelWisp2, a protein with cell adhesion and cell growth regulation properties upregu-
lated in our dataset was also found to be neuroprotective and promote neurite outgrowth in
vitro [30]. The upregulation of neuroprotective genes in the pEAE mouse model suggests that
this model can be used to investigate neuroprotective pathways in the progressive disease stage.
The Cholesterol Biosynthesis Pathway
The cholesterol biosynthesis pathway was identified as the most significantly regulated canoni-
cal pathway in the Ingenuity pathway analysis (Table 3), with 17/27 genes assigned to this path-
way significantly downregulated. Importantly, some of the cholesterol biosynthesis pathway
genes, such as the genes encoding the cholesterol synthesising enzymes isopentenyl-diphos-
phate delta isomerase (Idi1), 3-hydroxy-3-methyglutaryl-coenzyme A synthase 1 (HMG-CoA
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reductase, Hmgcs1), methylsterol monoxygenase 1 (Sc4mol), 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (Hmgcr) and squalene epoxidase (Sqle) are in the list of the most signifi-
cantly downregulated genes in this analysis (Table 2).
Significant downregulation of the cholesterol biosynthesis genes during relapsing disease
has also been reported in MOG-induced EAE in Dark Agouti rats [69], as well as in the spinal
cord of MBP-induced EAE in Lewis rats [28]. In contrast to the MOG-induced EAE study
though, where only cholesterol biosynthesis genes were downregulated, in our model choles-
terol transport genes were also downregulated, indicating downregulation of additional com-
ponents of cholesterol metabolism in the pEAE model. HMG-CoA reductase, a cholesterol
rate-limiting enzyme has also been found downregulated in people with MS [80]. In the dys-
myelinating peroxisome-proliferator-activated receptor gamma coactivator 1 (PGC1α) knock-
out mouse model, brain cholesterol, its precursors, and the rate-limiting enzymes HMG CoA
synthase (Mcoln3) and HMG CoA reductase (Hmgcr), were downregulated [52]. There are two
possible mechanisms that may result in cholesterol biosynthesis downregulation in EAE. One
mechanism may involve the presence of cholesterol at lesions due to the breakdown of the cho-
lesterol-rich myelin membranes, leading to inhibition of its biosynthesising pathway and con-
tributing to remyelination inhibition. Cholesterol negatively regulates the transcription of
cholesterol biosynthesis genes [81]. Another mechanism involved in cholesterol biosynthesis
downregulation involves the activation of the immune system. It was recently shown that met-
abolic factors involved in cholesterol biosynthesis are downregulated to promote the expansion
and reorganisation of pro-inflammatory CD4+ Th17 cells in vivo [74].
The involvement of cholesterol synthesis rate-limiting enzymes in MS and EAE pathology
is also highlighted by the fact that HMG-CoA inhibitors ameliorate EAE and MS relapses by
inhibiting immune cell activation and migration through the blood-brain barrier [82]. Lova-
statin and simvastatin are HMG-CoA inhibitors taken to clinical studies for relapsing remitting
MS [83, 84]. However, more importantly, high dose simvastatin has recently been shown to
inhibit neurogeneration in secondary progressive MS [85], which is a disease stage that is not
typically responsive to immune activation or blockage of peripheral immune responses enter-
ing the brain [8]. The finding here that cholesterol biosynthesis pathways are highly dysregu-
lated in pEAE, which is mostly unresponsive to peripheral immunomodulation, may support
the value of HMG-CoA inhibitors in progressive MS and provide a tool for mechanistic studies
to understand the neuroprotective effects of statins. The transcriptomic data available clearly
indicate a downregulation of this pathway but further investigation is needed to determine the
physiological consequences of this downregulation.
Additionally Ch25h, a gene involved in cholesterol metabolism, was upregulated in the
pEAE mouse. Cholesterol 25-hydroxylase is involved in lipid metabolism, catalyses the forma-
tion of 25-hydroxycholesterol from cholesterol and represses cholesterol biosynthetic enzymes
[86]. Thus its upregulation agrees with the preferential downregulation of the cholesterol bio-
synthesis pathway. Ch25h has also been proposed as a susceptibility gene for Alzheimer’s dis-
ease [36] and its deletion can significantly attenuate EAE disease course by limiting trafficking
of pathogenic CD4+ T lymphocytes to the central nervous system [37]. Lastly a lipid storage
regulator, Plin4 is upregulated in pEAE and with no identified role in EAE or MS pathology its
potential role in cholesterol or LXR/RXR metabolism (see below) would be worth
investigating.
The LXR/RXR Activation Pathway
The LXR/RXR activation pathway was also significantly regulated in the pEAE model with 23/
121 genes involved in this pathway downregulated and 4/121 upregulated. Genes involved in
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this pathway include Ttr (transthyretin), the most significantly downregulated gene in this
study (Table 2), the HMG-CoA reductase gene, as well as the highly downregulated genes
Sc4mol and Ldlr. The liver X receptors (LXRs) and the retinoid X receptors (RXRs) are obligate
heterodimers that form ligand-activated nuclear transcription factors that regulate lipid
homeostasis, including cholesterol metabolism [87]. The LXR pathway is emerging as a critical
pathway in oligodendrocyte precursor cell (OPC) differentiation [67]. It was found that the
RXR-γ receptor was significantly upregulated in the regenerative phase of remyelination in a
toxin-induced demyelination model in rats, while the LXR/RXR activation pathway was signif-
icantly regulated [67]. This positive regulation of remyelination is a promising pharmaceutical
target. The suppression of the LXR/RXR activation pathway identified in the pEAE model,
may contribute to the limited remyelination observed in this model and suggests that upregula-
tion of relevant components of the LXR/RXR pathway may promote remyelination.
Interestingly and perhaps not surprisingly, the LXR/RXR activation pathway was also highly
regulated in the transcriptomic analysis of T cells isolated from acute mouse EAE [74], impli-
cating LXR/RXR signaling in immune cell responses. In addition to genes such as Srebf1,
Hmgcr, or Cyp51a1 which are involved in cholesterol biosynthesis, genes such as Abca1, Srebf1
and Lpl which are involved in cholesterol transport were also found regulated in Th17 cells, as
well as in our dataset, implicating cholesterol transport in the disease progression. mRNA levels
of LXR-β were also found increased in MS patient peripheral blood mononuclear cells [88].
Additionally, combination of LXR and RXR or PPARγ and RXR agonists can inhibit microglial
and astrocyte inflammatory responses in vitro and in EAE models [89–92]. LXR/RXR signaling
provides promising therapeutic options in MS, but much is still unclear about the role of this
signaling pathway in specific cell populations and different phases of disease progression. Tran-
scriptomic analysis of acute and chronic models can help with the elucidation of LXR/RXR sig-
naling in MS.
Transthyretin, encoded by the Ttr gene is associated with the LXR/RXR activation pathway
and is highly downregulated in our dataset. Transthyretin transfers thyroxin from the blood to
the brain, where thyroxin is essential for oligodendrocyte maturation [49]. Thus the low tran-
scripts of transthyretin in EAE spinal cord may be one factor contributing to remyelination
failure. Transthyretin is highly expressed in MS patient serum [93], suggesting that there may
be a failure in transthyretin transfer from the blood to the CSF and the brain and that pharma-
cological enhancement of that pathway may increase thyroxin availability in the brain and spi-
nal cord and promote remyelination in MS patients.
The pEAEMouse Model Transcriptome Compared to Other EAE Models
The pEAE Biozzi ABH mouse model exhibits a reproducible relapsing-remitting disease
accompanied by demyelination, gliosis, glial cell activation, axonal and neuronal loss, followed
by a slowly accumulating permanent neurological deficit [16, 17], which was examined here.
The pEAE mouse model has been used for the study of mechanisms involved in the accumula-
tion of neurological damage. Genes and pathways relevant to MS pathology are identified in
this model, but its comparison to other EAE models can provide a lot of information about
genes and processes unique to this model or common with other progressive phenotypes. The
comparison of pEAE with a MOG-induced relapsing EAE study in Dark Agouti rats during the
acute, remitting and relapsing stages of the disease [69] revealed some similarities between the
two models, and especially similarities between upregulated genes (Fig 4, S3 Table). 66% of the
upregulated genes in the relapsing phase of the MOG-EAE model were common with the
pEAE model, opposed to 42% in the acute phase and 33% in the remitting phase. This supports
higher similarities between the relapsing EAE phenotype and the pEAE phenotype, as such
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active inflammation and progressive lesions co-exist in progressive MS, although the equilib-
rium is shifted to chronic glial cell lesions [75]. A limitation of our study was that only tissue
from the secondary progressive phase of the disease was studied. Additional studies of different
disease stages of the pEAE mouse model would help identify the molecular pathways unique in
the progressive stage, as well as give even more information regarding similarities and differ-
ences between relapsing-remitting EAE models. On the other hand, our study identified a
larger number of differentially expressed genes in comparison to older microarray studies.
Another interesting subject for further investigation would be the identification of the tran-
scriptome of the different cellular populations of the pEAE spinal cord. RNAseq analysis has
made it possible to collect small amounts of RNA and perform transcriptomic analysis. The
comparison of our study with an RNAseq study of the transcriptome of monocyte derived or
resident CNS microglia [71] in MOG-induced EAE revealed a wealth of information about
macrophage-specific pathways regulated in pEAE, as well as pathways uniquely identified in
pEAE (Fig 6, S6 Table).
MS Susceptibility Genes Significantly Regulated in Progressive EAE
pEAE is an experimental autoimmune mouse model that recapitulates key pathological fea-
tures of secondary progressive MS, such as demyelination, remyelination, gliosis, axonal and
neuronal loss [17]. Genes significantly modulated in pEAE are involved in disease mechanisms
that are similar to MS pathology. To identify molecules in pEAE that may point to molecular
pathways specifically relevant to MS pathology, we compared the pEAE transcriptome with
209 MS susceptibility genes [74] and identified 39 significantly regulated genes that are MS sus-
ceptibility genes (Fig 7). This list of genes (Fig 7B) comprises of immune-related genes such as
the ligand C3, the cell surface proteins Cd37, Cd48, Cd86, Fcrls, Ltbr, Vcam1, Ccdc88b and the
cytoplasmic proteins Coro1a, Ifi30, Plek,MertK and Dab2. Tnfaip3, Tnfrsf14, Tnfrsf1a and
Traf3a are genes that are involved in the tumor necrosis factor signaling processes. TNF signal-
ing is central to MS and EAE pathology. Thus it comes as no surprise that in the pEAE mouse
model TNF was identified as the most significantly regulated upstream regulator in the IPA
analysis (data not shown, available on request). The transcription factors Hhex, Irf8,Maf,
Stat3, Zfp36l1, Zfp36l2 and the transcription regulators Ikzf1, Ptrf Sp110 were also upregulated
in pEAE and although most of them are involved in immune-pathway transcription, their care-
ful investigation could reveal additional functions. Sox8, the only transcription factor in the list
which was downregulated in the pEAE mouse, promotes cellular differentiation and has a pos-
sible role in nervous system development.
MS susceptibility genes regulated in the pEAE without a clearly identified role in MS include
the non-voltage gated sodium channel Scnn1a, the solute carrier Slc44a2, the lysosomal cyste-
ine proteinase Ctsh, the serine biosynthesis enzyme Phgdh, and the mitochondrialHmgsc2, an
enzyme which controls ketogenesis. The proton sensing receptor Gpr65, involved in osteoclast
differentiation, which is one of the most upregulated genes in the pEAE mouse model is also an
MS susceptibility gene. Iqgap1 is a scaffolding protein recognised as instrumental in cytoskele-
tal organisation and cell signaling [94]. Rgs14, a regulator of G protein signaling found upregu-
lated in pEAE was identified as a gene differentially regulated in pathogenic CD4+ T cells [74].
Interestingly it is also recognised as a neuronal suppressor of long-term potentiation of synap-
tic transmission in the hippocampus [95]. The neuronal role of Rgs14 opens a question as to
whether its upregulation in pEAE may involve neuronal processes. Quantification of Rgs14 lev-
els in neuronal cells in MS or EAE will help to resolve this question. The same applies to Scap2,
a gene with documented expression in both neurones and immune cells. Scap2 is a Src kinase-
associated phosphoprotein involved in integrin-stimulated cytoskeleton rearrangement [96],
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but it is also involved in neuronal differentiation [97]. A glioblastoma susceptibility locus,
Phldb1 [98] was also present in the list of MS susceptibility genes downregulated in the pEAE
mouse. The identification of these MS susceptibility genes in the pEAE mouse model opens the
door to their functional study in a mouse model which recapitulates some of the important
clinical features of MS.
Conclusion
The aim of this study was to transcriptionally characterise the progressive Biozzi ABH EAE
mouse model in an unbiased manner and identify genes and disease processes that may be spe-
cific to this mouse model and that may recapitulate some of the MS features more adequately
than other disease models. Importantly, genes specifically regulated in the chronic phenotype
of EAE were identified and their role in the chronic disease phase as well as their potential as
therapeutic targets can be studied further.
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